Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.
Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C. Cucè M, et al. Among authors: rossi m. J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9. J Hematol Oncol. 2019. PMID: 30898137 Free PMC article.
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.
Roberti R, Iannone LF, Palleria C, Curcio A, Rossi M, Sciacqua A, Armentaro G, Vero A, Manti A, Cassano V, Russo E, De Sarro G, Citraro R. Roberti R, et al. Among authors: rossi m. Front Pharmacol. 2021 May 26;12:684638. doi: 10.3389/fphar.2021.684638. eCollection 2021. Front Pharmacol. 2021. PMID: 34122113 Free PMC article. Review.
Molecular targets for the treatment of multiple myeloma.
Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Tassone P, Caraglia M. Rossi M, et al. Curr Cancer Drug Targets. 2012 Sep;12(7):757-67. doi: 10.2174/156800912802429300. Curr Cancer Drug Targets. 2012. PMID: 22671925 Review.
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P. Morelli E, et al. Among authors: rossi m. Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11. Blood. 2018. PMID: 29997223 Free PMC article.
6,424 results